

## ECONOMIC EVIDENCE PROFILES - Computerised cognitive behavioural therapy for Panic Disorder

Clinical / economic question: CCBT vs waiting list for panic disorder

Internet Psychiatri versus waiting list							
Study & country	Limitations	Applicability	Other comments	Incremental cost (£) <sup>1</sup>	Incremental effect	ICER (£/effect) <sup>1</sup>	Uncertainty <sup>1</sup>
Guideline analysis (model 3) UK	Minor limitations <sup>2</sup>	Directly applicable <sup>3</sup>	<ul style="list-style-type: none"> <li>Time horizon: 1 year</li> </ul>	£115.62	0.052	£2,216/QALY	Probability of Internet Psychiatri being cost-effective at £20,000/QALY: 85.3%

1. Costs expressed in 2009 UK pounds

2. Limited evidence base (2 RCTs); intervention currently not available in the UK

3. Analysis conducted to assist guideline development; NHS & personal social services perspective; QALYs estimated based on EQ-5D

Clinical / economic question: CCBT vs information control for panic disorder

Panic online versus information control							
Study & country	Limitations	Applicability	Other comments	Incremental cost (£) <sup>1</sup>	Incremental effect	ICER (£/effect) <sup>1</sup>	Uncertainty <sup>1</sup>
Klein <i>et al.</i> , 2006 Australia	Potentially serious limitations <sup>2</sup>	Partially applicable <sup>3</sup>	<ul style="list-style-type: none"> <li>Time horizon: 6 weeks</li> <li>Cost-consequence analysis</li> </ul>	£141	See GRADE clinical profile above	Non-Applicable	No statistical analysis of costs
Guideline analysis (model 1) UK	Minor limitations <sup>4</sup>	Directly applicable <sup>5</sup>	<ul style="list-style-type: none"> <li>Time horizon: 1 year</li> </ul>	£354.96	0.046	£7,599/QALY	Probability of cost effectiveness at £20,000/QALY: 92%

1. Costs converted and uplifted to 2009 UK pounds, using PPP exchange rates (<http://www.oecd.org/std/ppp>) and the UK HCHS inflation index; assuming study cost year 2004.

2. Short time horizon; intervention costs only considered; various panic, anxiety and cognition outcomes measured (cost-consequence analysis)

3. Australian study; narrow perspective (intervention costs only considered); local prices used; no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence

4. Limited evidence base (2 RCTs); intervention currently not available in the UK

5. Analysis conducted to assist guideline development; NHS & personal social services perspective; QALYs estimated based on EQ-5D

Clinical / economic question: CCBT versus relaxation for panic disorder

Fear Fighter (FF) versus relaxation							
Study & country	Limitations	Applicability	Other comments	Incremental cost (£) <sup>1</sup>	Incremental effect	ICER <sup>1</sup> (£/effect)	Uncertainty <sup>1</sup>
Kartenhaler <i>et al.</i> , 2006 UK	Minor limitations <sup>2</sup>	Partially applicable <sup>3</sup>	<ul style="list-style-type: none"> <li>Time horizon: 12 months</li> </ul>	£173	0.058QALYs	£2,980/ QALY	Probability of relaxation being cost-effective vs. FF or clinician-led CBT at a threshold of £30,000/QALY: 0%
McCrone <i>et al.</i> , 2009 UK	Potentially serious limitations <sup>4</sup>	Partially applicable <sup>5</sup>	<ul style="list-style-type: none"> <li>Time horizon: 14 weeks</li> <li>Two analyses using:                             <ul style="list-style-type: none"> <li>a. main problem ratings</li> <li>b. global phobia ratings</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>a. £144-£245</li> <li>b. £150-£251</li> </ul>	<ul style="list-style-type: none"> <li>a. 3.24</li> <li>b. 1.88</li> </ul>	<ul style="list-style-type: none"> <li>a. £44-£76/mean improvement in main problem rating</li> <li>£80-£133/mean improvement in global phobia rating</li> </ul>	Probability of FF being more cost-effective than relaxation: <ul style="list-style-type: none"> <li>a. 50% at a threshold of £42-£77 per unit of main problem rating</li> <li>b. 50% at a threshold of £77-£137 per unit of global phobia rating</li> </ul>

1. Costs uplifted to 2009 UK pounds using the UK HCHS inflation index.
2. QALYs estimated from data on the self-reported global phobia item; panic symptoms not necessarily captured; short time horizon; resource use estimates based on manufacturers and assumptions
3. Study population not entirely relevant (people with panic phobia); HRQoL scores taken from European community-based mental health survey; overall state of panic disorder valued
4. Short time horizon; intervention costs only considered; outcomes measured as improvements in main symptoms & global phobia ratings; potential conflict of interest
5. Study population not entirely relevant (people with panic or phobic disorder); narrow perspective (intervention costs only considered); no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence

Clinical / economic question: CCBT (Panic Online, PO) versus therapist-assisted self-administered CBT for panic disorder

Panic Online versus therapist-assisted self-administered CBT							
Study & country	Limitations	Applicability	Other comments	Incremental cost (£) <sup>1</sup>	Incremental effect	ICER (£/effect)	Uncertainty
Klein <i>et al.</i> , 2006 Australia	Potentially serious limitations <sup>2</sup>	Partially applicable <sup>3</sup>	<ul style="list-style-type: none"> <li>• Time horizon: 6 weeks</li> <li>• Cost-consequence analysis</li> </ul>	-£14	See GRADE clinical profile above	Non-Applicable	No significant difference in costs

1. Costs converted and uplifted to 2009 UK pounds, using PPP exchange rates (<http://www.oecd.org/std/ppp>) and the UK HCHS inflation index; assuming study cost year 2004.
2. Short time horizon; intervention costs only considered; various panic, anxiety and cognition outcomes measured (cost-consequence analysis)
3. Australian study; narrow perspective (intervention costs only considered); local prices used; no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence

Clinical / economic question: CCBT vs face-to-face CBT for panic disorder

<b>Fear Fighter (FF) versus face-to-face CBT</b>							
Study & country	Limitations	Applicability	Other comments	Incremental cost (£) <sup>1</sup>	Incremental effect	ICER (£/effect) <sup>1</sup>	Uncertainty <sup>1</sup>
Kartenhaler <i>et al.</i> , 2006 UK	Minor limitations <sup>2</sup>	Partially applicable <sup>3</sup>	<ul style="list-style-type: none"> <li>Time horizon: 12 months</li> </ul>	-£240	- 0.011 QALYs	£22,000/ QALY	Probability of FF being cost-effective at a cost-effectiveness threshold of £30,000/QALY: 39%
McCrone <i>et al.</i> , 2009 UK	Potentially serious limitations <sup>4</sup>	Partially applicable <sup>5</sup>	<ul style="list-style-type: none"> <li>Time horizon: 14 weeks</li> <li>Two analyses using:                             <ul style="list-style-type: none"> <li>a. main problem ratings</li> <li>b. global phobia ratings</li> </ul> </li> </ul>	a. -£139 to -£234 b.- £133 to -£234	a. 0.03 b. -0.64	a. FF dominant b. £208-£366/ mean improvement in global phobia rating	Not reported
<b>Panic Online (PO) versus face-to-face CBT</b>							
Guideline analysis (model 2) UK	Minor limitations <sup>6</sup>	Directly applicable <sup>7</sup>	<ul style="list-style-type: none"> <li>Time horizon: 1 year</li> </ul>	-£303.00	-0.023	£126,849/QALY	Probability of PO being cost-effective at £20,000/QALY: 71%
<b>Internet Psychiatri versus face-to-face CBT</b>							
Guideline analysis (model 4) UK	Minor limitations <sup>6</sup>	Directly applicable <sup>7</sup>	<ul style="list-style-type: none"> <li>Time horizon: 1 year</li> </ul>	-£433.50	0.012	cCBT dominant	Probability of Internet Psychiatri being cost-effective at £20,000/QALY: 95%

- Costs uplifted to 2009 UK pounds using the UK HCHS inflation index.
- QALYs estimated from data on the self-reported global phobia item; panic symptoms not necessarily captured; short time horizon; resource use estimates based on manufacturers and assumptions
- Study population not entirely relevant (people with panic phobia); HRQoL scores taken from European community-based mental health survey; overall state of panic disorder valued
- Short time horizon; intervention costs only considered; outcomes measured as improvements in main symptoms & global phobia ratings; potential conflict of interest
- Study population not entirely relevant (people with panic or phobic disorder); narrow perspective; no QALYs estimated but outcome measures considered relevant in guideline systematic review of clinical evidence
- Limited evidence base (1 RCT); intervention currently not available in the UK
- Analysis conducted to assist guideline development; NHS & personal social services perspective; QALYs estimated based on EQ-5D